Prediction of a Null Response to Pegylated Interferon alpha-2b Plus Ribavirin in Patients with High Viral Load Genotype 1b Hepatitis C
Gut and Liver
;
: 421-427, 2014.
Article
in English
| WPRIM
| ID: wpr-175278
ABSTRACT
BACKGROUND/AIMS:
The present study aimed to clarify whether virological response within 2 weeks after therapy initiation can predict a null response to pegylated interferon alpha-2b plus ribavirin therapy in patients with high viral load genotype 1b hepatitis C.METHODS:
The participants consisted of 72 patients with high viral load genotype 1b. The dynamics of viral load within 2 weeks were measured.RESULTS:
Significant differences between null responders and nonnull responders were noted for interleukin (IL)-28B genotype, amino acid 70 substitution, alpha-fetoprotein, low-density lipoprotein cholesterol, hyaluronic acid, and viral response. The area under the curve (AUC) for the receiver operating characteristic curve of the hepatitis C virus (HCV) RNA level decline at 2 weeks (AUC=0.993) was the highest among the factors predicting the null response. When the cutoff value for the HCV RNA level decline at 2 weeks was set at 0.80 log, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy in predicting a null response were 82%, 96%, 82%, 96%, and 94%, respectively. In comparison, values for the non-TT and mutant type of amino acid 70 substitution were similar to those for HCV RNA level decline at 2 weeks.CONCLUSIONS:
Virological response at 2 weeks or the combination of IL-28B and amino acid 70 substitution are accurate predictors of a null response.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Antiviral Agents
/
Polyethylene Glycols
/
Ribavirin
/
Recombinant Proteins
/
RNA, Viral
/
Administration, Oral
/
Prospective Studies
/
Treatment Outcome
/
Interferon-alpha
/
Area Under Curve
Type of study:
Observational study
/
Prognostic study
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
Language:
English
Journal:
Gut and Liver
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS